Search

Positron emission tomography (PET) imaging studies in laboratory animals are almost always performed under isoflurane anesthesia to ensure that the subject stays still during the image acquisition. Isoflurane is effective, safe, and easy to use, and it is generally assumed to not have an impact on the imaging results. Motivated by marked differences observed in the brain uptake and metabolism of the PET tracer 3‐[18F]fluoro‐4‐aminopyridine [(18F]3F4AP) between human and nonhuman primate studies, this study investigates the possible effect of isoflurane on this process. Mice received [18F]3F4AP injection while awake or under anesthesia and the tracer brain uptake and metabolism was compared between groups. A separate group of mice received the known cytochrome P450 2E1 inhibitor disulfiram prior to tracer administration. Isoflurane was found to largely abolish tracer metabolism in mice (74.8 ± 1.6 vs. 17.7 ± 1.7% plasma parent fraction, % PF) resulting in a 4.0‐fold higher brain uptake in anesthetized mice at 35 min post‐radiotracer administration. Similar to anesthetized mice, animals that received disulfiram showed reduced metabolism (50.0 ± 6.9% PF) and a 2.2‐fold higher brain signal than control mice. The higher brain uptake and lower metabolism of [18F]3F4AP observed in anesthetized mice compared to awake mice are attributed to isoflurane's interference in the CYP2E1‐mediated breakdown of the tracer, which was confirmed by reproducing the effect upon treatment with the known CYP2E1 inhibitor disulfiram. These findings underscore the critical need to examine the effect of isoflurane in PET imaging studies before translating tracers to humans that will be scanned without anesthesia. [ABSTRACT FROM AUTHOR]

Background: 4-Aminopyridine (4AP) is a medication for the symptomatic treatment of multiple sclerosis. Several 4AP-based PET tracers have been developed for imaging demyelination. In preclinical studies, [11C]3MeO4AP has shown promise due to its high brain permeability, high metabolic stability, high plasma availability, and high in vivo binding affinity. To prepare for the translation to human studies, we developed a cGMP-compatible automated radiosynthesis protocol and evaluated the whole-body biodistribution and radiation dosimetry of [11C]3MeO4AP in non-human primates (NHPs). Methods: Automated radiosynthesis was carried out using a GE TRACERlab FX-C Pro synthesis module. One male and one female adult rhesus macaques were used in the study. A high-resolution CT from cranial vertex to knee was acquired. PET data were collected using a dynamic acquisition protocol with four bed positions and 13 passes over a total scan time of ~ 150 min. Based on the CT and PET images, volumes of interest (VOIs) were manually drawn for selected organs. Non-decay corrected time-activity curves (TACs) were extracted for each VOI. Radiation dosimetry and effective dose were calculated from the integrated TACs using OLINDA software. Results: Fully automated radiosynthesis of [11C]3MeO4AP was achieved with 7.3 ± 1.2% (n = 4) of non-decay corrected radiochemical yield within 38 min of synthesis and purification time. [11C]3MeO4AP distributed quickly throughout the body and into the brain. The organs with highest dose were the kidneys. The average effective dose of [11C]3MeO4AP was 4.0 ± 0.6 μSv/MBq. No significant changes in vital signs were observed during the scan. Conclusion: A cGMP-compatible automated radiosynthesis of [11C]3MeO4AP was developed. The whole-body biodistribution and radiation dosimetry of [11C]3MeO4AP was successfully evaluated in NHPs. [11C]3MeO4AP shows lower average effective dose than [18F]3F4AP and similar average effective dose as other carbon-11 tracers. [ABSTRACT FROM AUTHOR]

Demyelination causes slowed or failed neuronal conduction and is a driver of disability in multiple sclerosis and other neurological diseases. Currently, the gold standard for imaging demyelination is MRI, but despite its high spatial resolution and sensitivity to demyelinated lesions, it remains challenging to obtain specific and quantitative measures of molecular changes involved in demyelination. To understand the contribution of demyelination in different diseases and to assess the efficacy of myelin-repair therapies, it is critical to develop new in vivo imaging tools sensitive to changes induced by demyelination. Upon demyelination, axonal K+ channels, normally located underneath the myelin sheath, become exposed and increase in expression, causing impaired conduction. Here, we investigate the properties of the K+ channel PET tracer [ 18 F]3F4AP in primates and its sensitivity to a focal brain injury that occurred three years prior to imaging. [ 18 F]3F4AP exhibited favorable properties for brain imaging including high brain penetration, high metabolic stability, high plasma availability, high reproducibility, high specificity, and fast kinetics. [ 18 F]3F4AP showed preferential binding in areas of low myelin content as well as in the previously injured area. Sensitivity of [ 18 F]3F4AP for the focal brain injury was higher than [ 18 F]FDG, [ 11 C]PiB, and [ 11 C]PBR28, and compared favorably to currently used MRI methods. [ABSTRACT FROM AUTHOR]

Abstract: The synthesis and structures of the first SiII‐donor supported manganese(II) complexes [L1]MnCl2, [L2]MnCl2, and [L3]2MnCl2 are reported, bearing a pincer‐type bis(NHSi)‐pyridine ligand L1, bidentate bis(NHSi)‐ferrocene ligand L2, and two monodentate NHSi ligands L3 (NHSi = N‐heterocyclic silylene), respectively. They act as unprecedented very active and stereoselective Mn‐based precatalysts (1 mol % loading) in transfer semi‐hydrogenations of alkynes to give the corresponding E‐olefins using ammonia–borane as a convenient hydrogen source under mild reaction conditions. Complex [L1]MnCl2 shows the best catalytic performance with quantitative conversion rates and excellent E‐stereoselectivities (up to 98 %) for different alkyne substrates. Different types of functional groups can be tolerated, except CN, NH2, NO2, and OH groups at the phenyl group of 1‐phenyl substituted alkynes. [ABSTRACT FROM AUTHOR]

Reaction of FeX2(thf)n (X = Cl n = 1.5, Br n = 2) with the chelating 1,1′-bis(silylenyl)-substituted ferrocene ligand SiFcSiA (Fc = ferrocendiyl, Si = PhC(NtBu)2Si:) furnishes the corresponding dihalido Fe(ii) complexes [(SiFcSi)FeX2] (X = Cl, 1 and X = Br, 2) in high yields. Reduction of the latter with an excess of KC8 in the presence of benzene and toluene leads to the unprecedented bis(silylene) stabilized Fe0 complexes [(SiFcSi)Fe-η6(C6H6)] 3 and [(SiFcSi)Fe-η6(C7H8)] 4, respectively. The 57Fe Mössbauer spectrum of 3 at 13 K exhibits parameters (σ = 0.3676 mm s−1; ΔEQ = 1.334 mm s−1) which are consistent with the presence of a pentacoordinated Fe0 atom in a pseudo trigonal–bipyramidal coordination environment, with two dative Si→Fe bonds and three coordination sites occupied by the η6-coordinated arene ligand. Results from DFT calculations, 57Fe Mössbauer parameters and the diamagnetic NMR spectra confirm the redox-innocent nature of these ligands and the zero oxidation state of the iron center. The catalytic ability of 3 was investigated with respect to ketone hydrogenation. In all cases, good to excellent yields to the corresponding alcohols were obtained at 50 °C and 50 bar H2 pressure. Electron-donating as well as -withdrawing substituents were tolerated with excellent to good yields. Conversions of bulkier ketones and unactivated aliphatic ketones lead merely to moderate yields. This represents the first example of a silylene-iron metal complex which has been utilized as a highly active precatalyst in the hydrogenation of ketones. The results underline the powerful ability of chelating bis(N-heterocyclic silylene) ligands acting as strong σ-donor ligands in stabilizing a new generation of low-valent, electron-rich transition metal complexes for catalytic transformations. [ABSTRACT FROM AUTHOR]